Ann: PharmAust to present at NWR Virtual Healthcare Conference, page-10

I concour with @darkhawk100
These presentations get better and better.
Biggest takeaway for me is that they are already preparing for pre-clinical in other neuro diseases- I assume Alzheimers, Huntingtons and maybe Parkinsons.
So we are possibly looking at a "wonder drug" for millions of patients worldwide. This is when the major news networks will line up, and I believe MT said there is an interview lined up with one of them already.
MT said USD150,000 per year for MPL is likely if it gets approved (this is less than Relivryo, etc)
So if other diseases are a go, then one million patients per year might be an aspirational target?
I just tried doing the sums how that might look versus a multiple for market cap, but the screen on my laptop isnt wide enough